AI and Light: How Spore.Bio is Transforming Industrial Quality Control by Eliminating Waiting Time
In the food, pharmaceutical, and cosmetics industries, contaminant detection still largely relies on traditional methods, requiring several days of laboratory analysis. These prolonged delays expose manufacturers to costly product recalls, regulatory sanctions, and heightened health risks. In response, Spore.Bio offers an instant on-site microbiological detection solution, combining artificial intelligence and photonics.
A Radical Transformation of Microbiological Control
Conventional methods take between 5 and 20 days to identify the presence of bacteria or other contaminants, a timeframe that is incompatible with today’s safety and responsiveness requirements. Spore.Bio eliminates this constraint with a patented technology that uses light to instantly detect bacterial loads in tested products.
The startup’s device leverages machine learning, advanced optics, and chemometrics to analyze samples in real time, without the need for incubation or external intervention. This approach allows quality teams to be alerted immediately in case of anomalies, significantly reducing contamination risks and preventing the unnecessary immobilization of entire stock batches awaiting validation.
Rapid Industry Adoption
Spore.Bio’s speed and efficiency have generated strong interest from industrial players. Over 200 factories are already waiting to integrate this technology. The startup is working with key actors in the food, pharmaceutical, and cosmetics sectors to refine its device iterations before scaling to full commercial deployment.
In parallel, Spore.Bio has secured a strategic partnership with the Institut Pasteur, a global leader in microbiology. This collaboration provides the startup with privileged access to Institut Pasteur’s strain library, allowing for continuous improvement of its detection models.
Accelerated Growth Momentum
Founded in 2023, Spore.Bio is led by Amine Raji (CEO), Maxime Mistretta (CTO), and Mohamed Tazi (COO).
The company recently acquired Greentropism, a startup specializing in spectroscopic analysis using AI, which had previously raised €3 million. This acquisition enables Spore.Bio to integrate advanced expertise in optics and predictive analytics, further strengthening its technological edge.
A €22 Million Series A to Scale Industrialization
To accelerate its development and industrialize its solution, Spore.Bio has just completed a €22 million Series A round, led by Singular. This funding brings the company’s total capital raised to €30 million since its inception. Investors include Point 72 Ventures, 1st Kind Ventures (Peugeot Family Office), Station F, and Lord David Prior (former Chairman of the NHS), alongside returning backers LocalGlobe, No Label Ventures, and Famille C (Clarins Family Office).
This capital will allow Spore.Bio to double its workforce to 50 researchers and engineers, finalize the industrialization of its solution, and prepare for its commercial launch by the end of 2025.
